Figure 4.
Pretreatment with malaria peptides increases susceptibility to in vitro human immunodeficiency virus (HIV) infection of malaria-sensitized Kenyan cord blood mononuclear cells (CBMCs). A, Frequency of CBMC samples productively infected with HIV in vitro. B, 32P-dTTP incorporation for individual CBMC samples. Lines indicate mean counts per min per microliter culture supernatant (cpm/µL) of samples with productive HIV infection. Twenty samples were used for all conditions except for in vitro CBMCs in media alone (media + virus), for which 10 malaria-sensitized samples and 10 malaria-nonsensitized samples were used. Malaria + virus, 3 days of culture in media containing pooled MSP1-42 peptides at 10 µg/mL each followed by HIVBaL exposure; PHA + virus, phytohemagglutinin stimulation preceeding viral exposure; media + virus, in vitro CBMCs in media alone for 3 days preceding viral exposure.